Search





Search





Markets
/
Stocks
/
nasdaq-qgen
/

Qiagen NV

QGEN

Add to Watchlist

32.690USD

-1.010-3.00%

Close 05/13, 16:00（ET）Quotes delayed by 15 min

6.74BMarket Cap

17.49P/E TTM



Qiagen NV

32.690

-1.010-3.00%

Overview Financials Discussions Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Discussions

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Qiagen NV

Currency: USD Updated: 2026-05-12

Key Insights

Qiagen NV's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 18 out of 383 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 46.99.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Qiagen NV's Score

Industry at a Glance

Industry Ranking

18 / 383

Overall Ranking

109 / 4490

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Qiagen NV Highlights

StrengthsRisks

Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 2.09B.

Undervalued

The company’s latest PE is 18.03, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 161.40M shares, decreasing 15.71% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 238.76K shares of this stock.

Analyst Rating

Based on 18 analysts

Buy

Current Rating

46.989

Target Price

+42.22%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-12

The current financial score of Qiagen NV is 9.17, ranking 11 out of 383 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 492.32M, representing a year-over-year increase of 1.83%, while its net profit experienced a year-over-year increase of 25.03%.

Score

Industry at a Glance

Previous score

9.17

Change



Financials

8.37

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.69

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

8.77

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Qiagen NV's Company Valuation

Currency: USD Updated: 2026-05-12

The current valuation score of Qiagen NV is 7.22, ranking 139 out of 383 in the Biotechnology & Medical Research industry. Its current P/E ratio is 18.03, which is 612.60% below the recent high of 128.51 and 3.89% above the recent low of 17.33.

Score

Industry at a Glance

Previous score

7.22

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 18/383

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-12

The current earnings forecast score of Qiagen NV is 6.89, ranking 319 out of 383 in the Biotechnology & Medical Research industry. The average price target is 50.00, with a high of 57.00 and a low of 45.00.

Score

Industry at a Glance

Previous score

6.89

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 17 analysts

Hold

Current Rating

46.265

Target Price

+41.79%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Qiagen NV

QGEN

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Ionis Pharmaceuticals Inc

IONS

Beigene Ltd

ONC

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-12

The current price momentum score of Qiagen NV is 6.80, ranking 186 out of 383 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 39.80 and the support level at 30.10, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.57

Change

0.23

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(1)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.216

Sell

RSI(14)

29.115

Sell

STOCH(KDJ)(9,3,3)

17.104

Oversold

ATR(14)

1.155

High Vlolatility

CCI(14)

-83.176

Neutral

Williams %R

97.245

Oversold

TRIX(12,20)

-0.868

Sell

StochRSI(14)

61.470

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

33.116

Sell

MA10

33.681

Sell

MA20

36.111

Sell

MA50

39.234

Sell

MA100

44.297

Sell

MA200

45.603

Sell

Institutional Confidence

Currency: USD Updated: 2026-05-12

The current institutional shareholding score of Qiagen NV is 7.00, ranking 83 out of 383 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 78.32%, representing a quarter-over-quarter increase of 4.59%. The largest institutional shareholder is The Vanguard, holding a total of 6.51M shares, representing 3.16% of shares outstanding, with 22.07% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

29.26M

+50.17%

MFS Investment Management

16.06M

-26.74%

T. Rowe Price International Ltd

8.01M

+12.05%

The Vanguard Group, Inc.

Star Investors

6.51M

-27.38%

EARNEST Partners, LLC

3.98M

-0.49%

Amundi Asset Management, SAS

3.92M

-0.57%

Boston Partners

3.78M

-0.89%

T. Rowe Price Associates, Inc.

Star Investors

3.33M

-0.13%

Risk Assessment

Currency: USD Updated: 2026-05-12

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Qiagen NV is 9.21, ranking 1 out of 383 in the Biotechnology & Medical Research industry. The company's beta value is 0.65. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Qiagen NV’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.